India Cuts Review Period for Clinical Trial Drug Manufacturing to 45 Days
The central government has reduced the approval timeline for applications to manufacture drugs meant for clinical trials, a move aimed at accelerating clinical research and drug development in India.
Boost Clinical Research | 22/01/2026 | By Darshana | 138
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy